You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:physicians [10.05.2018] – [Recent presentations] sallieqhome:physicians [11.15.2018] – [Representative presentations] sallieq
Line 20: Line 20:
 The MP uses multiple daily dosing of olmesartan medoxomil (Benicar, Olmecip, Olmetec) to re-activate the Vitamin D Nuclear Receptor, dislodging bacterial ligands in the process. This drug was developed as an Angiotensin II Receptor Blocker (ARB) but it has multiple actions in the human body when dosed as defined by Marshall. In addition to immunostimulation via the VDR, Olmesartan also reduces inflammatory cytokine production by inhibiting the NF kappa-B transcription pathway. This inhibits, among other things, the release of TNF-alpha, helping to protect the organs from effects of excessive inflammation.  The MP uses multiple daily dosing of olmesartan medoxomil (Benicar, Olmecip, Olmetec) to re-activate the Vitamin D Nuclear Receptor, dislodging bacterial ligands in the process. This drug was developed as an Angiotensin II Receptor Blocker (ARB) but it has multiple actions in the human body when dosed as defined by Marshall. In addition to immunostimulation via the VDR, Olmesartan also reduces inflammatory cytokine production by inhibiting the NF kappa-B transcription pathway. This inhibits, among other things, the release of TNF-alpha, helping to protect the organs from effects of excessive inflammation. 
  
-Additionally, several pulsed, low-dose, bacteriostatic oral antibiotics may **//optionally//** be used, in a minority of patients it may reduce IP, but is more likely to provoke it when after some months, it has declined to insignificance. Four bacteriostatic antibiotics: minocycline, clindamycin, sulfamethoxazole-trimethoprim (Bactrim DS), and demeclocycline (Declomycin) have been found useful for these outcomes. Minocycline directly acts in an immunosuppressive manner on the PXR nuclear receptor, and this biochemical action may be useful in pulsing immunopathology to (for example) a 48 hour cycle. Bactrim, however, may be avoided by anyone with a tendency to high potassium [[https://www.medpagetoday.com/primarycare/preventivecare/28976?pop=0&ba=1&xid=tbla-md-pcp|MedPage]] which is not under control by sodium bicarbonate (see [[home:othertreatments:sodium_bicarbonate|baking soda]])+Additionally, several pulsed, low-dose, bacteriostatic oral antibiotics may **//optionally//** be used, in a minority of patients it may reduce IP, but is more likely to provoke it when after some months, it has declined to insignificance. Four bacteriostatic antibiotics: minocycline, clindamycin, sulfamethoxazole-trimethoprim (Bactrim DS), and demeclocycline (Declomycin) have been found useful for these outcomes. Minocycline directly acts in an immunosuppressive manner on the PXR nuclear receptor, and this biochemical action may be useful in pulsing immunopathology to (for example) a 48 hour cycle. Bactrim, however, may be better avoided by anyone with a tendency to high potassium [[https://www.medpagetoday.com/primarycare/preventivecare/28976?pop=0&ba=1&xid=tbla-md-pcp|MedPage]] which is not under control by sodium bicarbonate (see [[home:othertreatments:sodium_bicarbonate|baking soda]])
      
  
Line 38: Line 38:
 Trevor Marshall and the rest of the Autoimmunity Research Foundation research team have been active in publishing papers and making presentations before learned bodies. Trevor Marshall and the rest of the Autoimmunity Research Foundation research team have been active in publishing papers and making presentations before learned bodies.
  
-Marshall's recent presentations can be viewed in order to get a more detailed description of the Marshall Pathogenesis and Protocol.+This material is provided in order to give a more detailed description of the Marshall Pathogenesis and Protocol.
  
 ^Presenter(s)    ^Date   ^Conference  ^Title   ^Location   ^ ^Presenter(s)    ^Date   ^Conference  ^Title   ^Location   ^
home/physicians.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.